If your new treatment has been approved to move on to human trials, you’re in a great position to begin ramping up your efforts. This should also include a commitment to developing your go to market strategy. However, at this point, most manufacturers are heavily focused on the trials themselves. After all, if the trials aren’t a success, there will be no new drug to release to the market.

That said, it’s important to also continue to invest in your commercialization strategy. Like the Preclinical phase, Phase I is primarily about learning. We can help in a number of ways.